* ImmuLogic Pharmaceutical Corp., of Waltham, Mass., adopted ashareholder rights plan. It said the plan was not in response to aspecific takeover threat or proposal.
* Japan Tobacco Inc., of Tokyo, said it developed a technology tointroduce genes into maize by using the microorganismAgrobacterium.
* OxiGene Inc., of New York, adjusted the price of the warrantsissued in connection with its initial public offering, reducing the pricefrom $9 to $8.39.
* Rhone-Poulenc Rorer Inc., of Collegeville, Pa., made a new drugsubmission in Canada seeking approval of Rilutek as a treatment foramyotrophic lateral sclerosis.
* Sheffield Medical Technologies Inc., of New York, entered into anoption and sponsored research agreement with Children's Hospital,of Boston, to develop clotrimazole and its metabolites for sickle cellanemia.
* Shreve Biotech, of Shreveport, La., was awarded a $100,000 smallbusiness grant to develop methods to enhance the immune responseagainst viral antigens.
* Tanox Biosystems Inc., of Houston, started a Phase I/IIa trial ofAD-519, a neutralizing monoclonal antibody to the C4 region ofgp120, an envelope glycoprotein of HIV.
* Telios Pharmaceuticals Inc., of San Diego, said all shareholdersvote in favor of the company's proposed reorganization plan.
* The Immune Response Corp., of Carlsbad, Calif., receivedclearance to test its rheumatoid arthritis therapy, which is designed toimmunize against T cells believed implicated in the disease, in a 90-patient Phase II trial.
* Zynaxis Inc., of Malvern, Pa., said it was awarded up to $750,000for a two-year Phase II small business innovation research grant toevaluate the coupling of its Zyn-Linker delivery molecules to heparin.
* Arris Pharmaceuticals Corp., of South San Francisco, said therewere no dose-limiting adverse effects from a Phase Ib study of APC366, a tryptase inhibitor for asthma.
* Cell Genesys Inc., of Foster City, Calif., and JT Immunotech USAInc., of San Mateo, Calif., a subsidiary of Tokyo-based JapanTobacco Inc., to extend for two years their 1991 agreement todevelop human antibody-producing mice. JT Immunotech is fundingthe research.
* Centocor Inc., of Malvern, Pa., is being sued by Paine WebberR&D Partners L.P. in New York for alleged breach of contractrelated to the 1993 suspension of Centoxin clinical trials for sepsis.
* Elan Corp. plc, of Athlone, Ireland, received a warning letter fromthe FDA that said Elan is not in compliance with current goodmanufacturing practices.
* Genzyme Transgenics Corp., of Framingham, Mass., completed itsacquisition of Biodevelopment Laboratories Inc., of Cambridge,Mass. _ a provider of testing and development services _ for $2.6million in stock, debt assumption of $2.7 million and otherconsiderations in a deal valued at $6 million. (See BioWorld Today,May 26, p. 2.)
* NeuroSearch A/S, of Glostrup, Denmark, said it raised $7.3 millionU.S. in a private placement that was undertaken in collaboration withCarnegie Kreditinstitut, of Denmark, and Carnegie FondskommissionAB, of Sweden. The company, working on drugs for central nervoussystem disorders, said this is the final private financing it intends tocomplete before going public.
* Seragen Inc., of Hopkinton, Mass., began a Phase II trial ofinterleukin-2 receptor-targeted fusion toxin in those with moderate tosevere plaque-type psoriasis. The randomized, double-blind, placebo-controlled trial will involve 60 patients.
* Symphony Pharmaceuticals Inc., of Malvern, Pa., was awarded a$1.7 million three-year grant from the National Institute of Standardsand Technology, to research the modulation of protein expression asa way to identify compounds for treatment of a variety of disease.
* QLT PhotoTherapeutics Inc., of Vancouver, Canada, received anapprovable letter from the FDA for the company's light activateddrug, Photofrin, as a palliative treatment for obstructing cancers ofthe esophagus. In addition, Canada approved the treatment for thesame indication.
* Sheffield Medical Technologies Inc., of Houston, began a PhaseI/II trial of its drug, RBC-CD4, for treatment of HIV at the JohnsHopkins University Medical Center in Baltimore. The drug uses CD4proteins, inserted in red blood cell membranes, to act as decoys,attracting HIV and removing the virus from the blood stream.
* Xenova Group plc, of Slough, England, said its AmericanDepository Shares now trade on the NASDAQ under the symbol,XNVAZ.
(c) 1997 American Health Consultants. All rights reserved.